Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2538-2546

  Welsh, Sarah J ^a   Titley, Jenny ^b   Brunton, Lisa ^a   Valenti, Melanie ^a   Monaghan, Paul ^b   Jackman, Ann L ^a   Aherne, G Wynne ^b,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Haddow Laboratories   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; ENZYME INHIBITOR; NOLATREXED; PEMETREXED; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ARTICLE; AUTOREGULATION; BLAST TRANSFORMATION; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; FLUOROURACIL; GLUTAMATES; GUANINE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED DBA; MICROSCOPY, CONFOCAL; NEOPLASM TRANSPLANTATION; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0034124895     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Grem, J. L. Fluorinated pyrimidines. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy, Principles and Practice, pp. 180-224. Philadelphia: J. B. Lippincott Co., 1990.
2. Takemura, Y., and Jackman, A. L. Folate based TS inhibitors in cancer chemotherapy. Anticancer Drugs, 8: 3-16, 1997.
3. Moertel, C. G. Chemotherapy for colorectal cancer. N. Eng. J. Med., 330: 1136-1143, 1994.
4. Gunasekara, N. S., and Faulds, D. Raltitrexed - a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs, 55: 423-435, 1998.
5. Jackman, A. L., Kimbell, R., Aherne, G. W., Brunton, L., Jansen, G., Stephens, T. C., Smith, M. N., Wardleworth, J. M., and Boyle, F. T. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res., 3: 911-921, 1997.
6. Rees, C., Beale, P., Plummer, R., Highley, M., Calvert, A. H., Judson, I., Smith, R., Hutchison, M., Averbuch, S., and Mayne, K. Phase I trial of ZD9331 given as a 30 minute infusion on days 1 and 8 with cycles repeated every 3 weeks. Ann. Oncol., S4: P628, 1998.
7. Rusthoven, J. J., Eisenhauer, E., Butts, C., Gregg, R., Dancey, J., and Fisher, B. Multitargeted antifolate LY231514 as first line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol., 17: 1194-1199, 1997.
8. Duch, D. S., Banks, S., Dev, I. K., Dickerson, S. H., Ferone, R., Heath, L. S., Humphreys, T., Knick, V., Pendergast, W., Singer, S., Smith, G. K., Waters, K., and Wilson, H. R. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res., 53: 810-818, 1993.
9. Rafi, I., Boddy, A. V., Calvete, J. A., Taylor, G. A., Newell, D. R., Bailey, N. P., Lind, M. J., Green, M., Hines, J., Johnston, A., Glendennin, N., and Calvert, A. H. Preclinical and Phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration to patients with solid tumors. J. Clin. Oncol., 16: 1131-1141, 1998.
10. Freemantle, S. J., Jackman, A. L., Kelland, L. R., Calvert, A. H., and Lunec, J. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br. J. Cancer, 71: 925-930, 1995.
11. Jackman, A. L., Kelland, L. R., Kimbell, R., Brown, M., Gibson, W., Aherne, G. W., Hardcastle, A., and Boyle, F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and two human cell lines. Br. J. Cancer, 71: 914-924, 1995.
12. Kohayshi, H., Takemura, Y., Miyachi, H., Skelton, L., and Jackman, A. L. Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors. Jpn. J. Cancer Res., 86: 1014-1018, 1995.
13. Takemura, Y., Gibson, W., Kimbell, R., Kobayshi, H., Miyachi, H., and Jackman, A. L. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug. J. Cancer Res. Clin. Oncol., 122: 109-117, 1996.
14. Takemura, Y., Kobayshi, H., Gibson, W., Kimbell, R., Miyachi, H., Jackman, A. L. The influence of drug exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukemia cells. Int. J. Cancer, 66: 29-36, 1996.
15. Rhee, M. S., Wang, Y., Nair, M. G., and Galivan, J. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res., 53: 2227-2230, 1993.
16. Chu, E., Koeller, D. M., Casey, J. H., Drake, J. C., Chabner, B. A., Elwood, P. C., Zinn, S., and Allegra, C. J. Auto-regulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl. Acad. Sci. USA, 90: 517-521, 1990.
17. Keyomarsi, K., Samet, J., Molnar, G., and Pardee, A. B. The TS inhibitor, ICI D1694. overcomes translational detainment of the enzyme. J. Biol. Chem., 268: 15142-15149, 1993.
18. Kitchens, M. E., Forsthoefel, A. M., Rafique, Z., Spencer, H. T., and Berger, F. G. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization - implications for autoregulation of translation. J. Biol. Chem., 274: 12544-12547, 1999.
19. Drake, J., Gress, R., Schwartz, G., and Allegra, C. 5-FU mediated thymidylate synthase induction in normal and malignant human cells. Proc. Am. Assoc. Cancer Res., 38: 3177, 1997.
20. O'Connor, B. M., Jackman, A. L., Crossley, P. H., Freemantle, S. E., Lunec, J., and Calvert, A. H. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N-10-propargyl-5,8,-dideazafolic acid - a novel folate based thymidylate synthase inhibitor. Cancer Res., 52: 1137-1143, 1992.
21. Skelton, L. A., Omerod, M. G., Titley, J., Kimbell, R., Brunton, L., and Jackman, A. L. A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus. Br. J. Cancer, 79: 1692-1701, 1999.
22. Iselt, M., Holtei, W., Hilgard, P. The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity. Drug Res., 39: 747-749, 1989.
23. Aherne, G. W., Hardcastle, A., Brown, S., Skelton, L. A., Findlay, M. P. N., and Jackman, A. L. The effect of thymidylate synthase (TS) inhibitors on TS protein expression in human tumour cell lines measured by ELISA. In: W. Pfleiderer and H. Rokos (eds.), Chemistry and Biology of Pteridines and Folates, pp. 407-410. Berlin: Blackwell Science, 1997.
24. Tolleson, W. H., Alibhai, M., Cisneros, R. J., and Dunlap, R. B. Comparison of ELISA with activity and ligand-binding methods for the determination of thymidylate synthase concentration. Bioconjugate Chem., 2: 327-332, 1991.
25. Johnston, P. G., Drake, J. C., Trepel, J., and Allegra, C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-Fluorouracil-sensitive and resistant human cancer cell lines. Cancer Res., 52: 4306-4312, 1992.
26. Cohen, SS. On the nature of thymineless death. Ann. NY Acad. Sci., 106: 292-301, 1971.
27. Chu, E., Zinn, S., Boarman, D., and Allegra, C. J. The interaction of g interferon and 5-FU in the H630 human colon carcinoma cell line. Cancer Res., 50: 5834-5840, 1990.
28. Swain, S. M., Lippman, M. E., Egan, E. F., Drake, J. C., Steinberg, S. M., and Allegra, C. J. 5-Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7: 890-899, 1989.
29. Jackman, A. L. Antifolate Drugs in Cancer Chemotherapy. New Jersey: Humana Press, 1999.
30. Johnston, P. G., Fisher, E. R., Rockett, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
31. Pestalozzi, B. C., Peterson, H. F., Gelber, R. D., Goldhirsch, A., Fusterson, B. A., Trihia, H., Lindtner, J., Cortes-Funes, H., Simmoncini, E., Hyrne, M. J., Golouh, R., Rudenstam, C. M., Castiglione-Gertsch, M., Allegra, C. J., and Johnston, P. G. Prognostic importance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol., 15: 1923-1931, 1997.
32. Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
33. Farrugia, D. C., Cunningham, D., Mitchell, F., Aherne, G. W., MacVicar, D., McKarthy, K., Norman, A. R., and Jackman, A. L. A pharmacodynamic study of the antifolate thymidylate synthase inhibitor Tomudex in advanced colorectal cancer. In: W. Pfeiderer and H. Rokos (eds.), Chemistry and Biology of Pteridines and Folates, pp. 241-244. Berlin: Blackwell Science, 1997.
34. Leichman, C. G., Lenz, H. J., Leichman, L., Dananberg, K. D., Baranda, J., Groschen, S., Boswell, W., Mitzger, R., Tan, M., and Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly Leucovorin. J. Clin. Oncol., 15: 3223-3229, 1997.
35. Lenz, H. J., Leichman, C. J., Dananberg, K. D., Danenberg, P. V., Groschen, S., Cohen, L., Laine, L., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J. Clin. Oncol., 14: 176-182, 1995.
36. Alexander, H. R., Grem, J. L., Hamiliton, J. M., Pass, H. I., Hong, M., Fraker, D. L., Steinberg, S. M., McAtee, N., Allegra, C. J., and Johnston, P. G. Thymidylate synthase protein expression. Cancer J. Sci. Am., I: 49-54, 1995.
37. Parise O., Jr., Janot, F., Luboinski, B., Masaad, L., Albin, N., Toussaint, C., Verjus, M. A., Bonnay, M., Gouyette, A., and Chabot, G. G. Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues. Head Neck, 16: 158-164, 1994.35.
38. Johnston, P. G., Mick, R., Recant, W., Behan, K. A., Dolan, E. Ratain, M., Beckmann, E., Weichselbaum, R. R., Allegra, C. J., and Yokes, E. E. Thymidylate synthase expression predicts for response to neoadjuvant induction chemotherapy in advanced head and neck cancers. J. Natl. Cancer Inst., 89: 308-313, 1997.
39. Clarke, J. L., Berger, S. L., Mittelman, A., and Berger, F. G. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat. Rep., 71: 261-265, 1997.
40. Washstein, W. L. Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil. Mol. Pharmacol., 25: 171-177, 1998.
41. Aherne, G. W., Ward, E., Dobinson, D., Hardcastle, A., and Jackman, A. L. Pharmacokinetics of a bolus injection of ZD9331, a non-polyglutamated thymidylate synthase (TS) inhibitor. Proc. Am. Assoc. Cancer Res., 37: 2605, 1996.
42. Aherne, G. W., Hardcastle, A., Ward, E., Brown, S., and Jackman, A. L. In vitro and in vivo pharmacology of the non-polyglutamated quinazoline antifolate thymidylate synthase (TS) inhibitor, ZD9331. Ann. Oncol., 7 (Suppl. 1): 308: 1996.
43. Ratain, M. J., Cooper, N., Smith, R., Vogelzang, N. J., Mani, S., Shulman, K., Lowe, P. G., and Averbuch, S. D. Phase I study of 2D9331: a novel thymidylate (TS) inhibitor. Proc. Am. Soc. Clin. Oncol., 16: 729, 1997.
44. Pestalozzi, B. C., McGinn, C. J., Kinsella, T. J., Drake, J. C., Glennon, M. C., Allegra, C. J., and Johnston, P. G. Increased thymidylate synthase protein-levels are principally associated with proliferation but not cell-cycle phase in asynchronous human cancer cells. Br. J. Cancer, 71: 1151-1157, 1995.
45. Findlay, M. P. N., Cunningham, D., Morgan, G., Clinton, S., Hardcastle, A., and Aherne, G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br. J. Cancer, 75: 903-909, 1997.
46. Spears, C. P., Gustavsson, B. G., and Mitchel, M. S. Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res., 44: 4144-4150, 1984.
47. Behrend, E., Ferguson, P., DeMoor, J., Collins, O., Dean, N., Vincent, M., and Koropatnick, J. Effects of antisense oligodeoxynucleotides (ODNs) targeted against thymidylate synthase (TS) on the growth and Tomudex sensitivity of human tumor cell lines in vivo. Proc. Am. Assoc. Cancer Res., 40: P137, 1999.
48. Schmitz, J. C., Agrawal, S., and Chu, E. Cytotoxicity and suppression of thymidylate synthase expression in human colon cancer RKO cells by a 2′-O-methyl RNA antisense oligoribonucleotide. Proc. Am. Assoc. Cancer Res., 40: P138, 1999.
49. Ferguson, P. J., Collins, O., Dean, N. M., DeMoor, J., Chen, S-L., Vincent, M. D., and Koropatnick, J. Proc. Am. Assoc. Cancer Res., 40: P139, 1999.